Lilly strengthens Zyprexa warnings

Eli Lilly is owning up to Zyprexa's ills in new warnings added to the medicine's label. The schizophrenia drug will now be tagged with weight gain, high blood sugar high cholesterol, and other metabolic problems.

It's the first time Zyprexa's label has acknowledged that it causes high blood sugar more readily than other atypical antipsychotics. In fact, Lilly has argued against it, saying that the difference wasn't proven. The label also admits that weight gain may continue for as long as two years, rather than plateauing in a few months as previously stated.

Though Zyprexa has steadily lost market share since 2004 because of side effects, it still delivered $2.3 billion in worldwide sales the first half of this year.

- see Lilly's release
- read the article from the New York Times

Related Articles:
Lilly CEO: Use IT to boost drug safety. Report
Eli Lilly pairs with GE to study cancer drugs. Report
Lilly developing biotech drugs the old-fashioned way. Report
Lilly accused of promoting off-label Zyprexa use. Report
NYT accuses Lilly of hiding safety problems. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Novartis and GBT won long-awaited approvals for sickle cell treatments, but ICER says the drugs are far too expensive based on their clinical benefit.